Cargando…

Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Arif, Tasleem, Vasilkovsky, Lilia, Refaely, Yael, Konson, Alexander, Shoshan-Barmatz, Varda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114110/ https://www.ncbi.nlm.nih.gov/pubmed/28918049 http://dx.doi.org/10.1016/j.omtn.2017.08.008

Ejemplares similares

Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo
por: Arif, Tasleem, et al.
Publicado: (2014)

Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells
por: Arif, Tasleem, et al.
Publicado: (2019)

VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor Microenvironment
por: Zerbib, Erez, et al.
Publicado: (2021)

Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
por: Arif, Tasleem, et al.
Publicado: (2018)

The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link
por: Amsalem, Zohar, et al.
Publicado: (2020)

Selective induction of cancer cell death by VDAC1‐based peptides and their potential use in cancer therapy
por: Shteinfer‐Kuzmine, Anna, et al.
Publicado: (2018)

Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma
por: Shteinfer-Kuzmine, Anna, et al.
Publicado: (2017)

VDAC1: from structure to cancer therapy
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2012)

Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept
por: Arif, Tasleem, et al.
Publicado: (2019)

Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks
por: Pandey, Swaroop Kumar, et al.
Publicado: (2022)

VDAC1 at the Intersection of Cell Metabolism, Apoptosis, and Diseases
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2020)

VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

VDAC1 and the TSPO: Expression, Interactions, and Associated Functions in Health and Disease States
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2019)

Targeting Liver Cancer and Associated Pathologies in Mice with a Mitochondrial VDAC1-Based Peptide
por: Pittala, Srinivas, et al.
Publicado: (2018)

Editorial: Uncovering the Function of the Mitochondrial Protein VDAC in Health and Disease: From Structure-Function to Novel Therapeutic Strategies
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism
por: Klapper-Goldstein, Hadar, et al.
Publicado: (2020)

Apoptotic proteins with non-apoptotic activity: expression and function in cancer
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2023)

A VDAC1-Derived N-Terminal Peptide Inhibits Mutant SOD1-VDAC1 Interactions and Toxicity in the SOD1 Model of ALS
por: Shteinfer-Kuzmine, Anna, et al.
Publicado: (2019)

Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

The Multicellular Effects of VDAC1 N-Terminal-Derived Peptide
por: Anand, Uttpal, et al.
Publicado: (2022)

Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2021)

The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus
por: Pittala, Srinivas, et al.
Publicado: (2020)

Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS
por: Shteinfer-Kuzmine, Anna, et al.
Publicado: (2022)

A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

In vivo silencing of alpha-synuclein using naked siRNA
por: Lewis, Jada, et al.
Publicado: (2008)

Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
por: Vollmann, Elisabeth H., et al.
Publicado: (2017)

Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells
por: Zhang, Enming, et al.
Publicado: (2019)

VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia
por: Prezma, T, et al.
Publicado: (2013)

The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing
por: Strapps, Walter R., et al.
Publicado: (2010)

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
por: Jayaraman, Muthusamy, et al.
Publicado: (2012)

Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011)

siRNA-induced ABCE1 silencing inhibits proliferation and invasion of breast cancer cells
por: HUANG, BO, et al.
Publicado: (2014)

Silencing of DLGAP5 by siRNA Significantly Inhibits the Proliferation and Invasion of Hepatocellular Carcinoma Cells
por: Liao, Weijia, et al.
Publicado: (2013)

siRNA-mediated stathmin1 silencing inhibits proliferation of prostate carcinoma cell line
por: AKSOY, Asude, et al.
Publicado: (2022)

The Mitochondrial Voltage-Dependent Anion Channel 1, Ca(2+) Transport, Apoptosis, and Their Regulation
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
por: Verma, Ankit, et al.
Publicado: (2022)

Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and Treatment
por: Admoni-Elisha, Lee, et al.
Publicado: (2016)

Correction: Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
por: Verma, Ankit, et al.
Publicado: (2023)

SMAC/Diablo controls proliferation of cancer cells by regulating phosphatidylethanolamine synthesis
por: Pandey, Swaroop Kumar, et al.
Publicado: (2021)

Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma
por: Tong, Wing Yin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8n50phld3i0hpbnhj8afvnpl09